Skip Navigation

Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer: Evaluation of the Optimal Dose, Safety, and Efficacy of Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy ? LIVIGNO-4

Brief Summary

Type:
Lung Cancers

Study Type:
Treatment

Phase:
II/III

ClinicalTrials.gov Identifier:
NCT06236438

Study #:
STUDY00160697

Start Date:
Nov 14, 2024

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT06236438

View Complete Trial Details & Eligibility at ClinicalTrials.gov